Segment Information (Tables)

9 Months Ended

Sep. 30, 2013

Revenues, Cost Of Services And Products, And Gross Margins For Operating Segments


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Revenues:
Medical devices	$	18,833	$	16,893	$	56,824	$	50,043
Preservation services		17,417		16,399		48,411		48,371
Other^a		--		137		71		504
Total revenues		36,250		33,429		105,306		98,918

Cost of products and preservation services:
Medical devices		3,544		3,114		10,730		8,300
Preservation services		9,357		9,005		26,472		26,645
Total cost of products and preservation services		12,901		12,119		37,202		34,945

Gross margin:
Medical devices		15,289		13,779		46,094		41,743
Preservation services		8,060		7,394		21,939		21,726
Other^a		--		137		71		504
Total gross margin	$	23,349	$	21,310	$	68,104	$	63,973

Summary Of Net Revenues By Product


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2013		2012		2013		2012
Products:
BioGlue and BioFoam	$	14,232	$	12,725	$	43,238	$	39,858
PerClot		882		734		2,686		2,069
Revascularization technologies		2,353		2,060		6,837		6,107
HeRO Graft		1,366		1,374		4,063		2,009
Total products		18,833		16,893		56,824		50,043

Preservation services:
Cardiac tissue		8,572		8,239		22,035		22,662
Vascular tissue		8,845		8,160		26,376		25,709
Total preservation services		17,417		16,399		48,411		48,371

Other^a		--		137		71		504
Total revenues	$	36,250	$	33,429	$	105,306	$	98,918

___________________

aThe “Other” designation includes grant revenue.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details